8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 2, 2005

DYNAVAX TECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation) 000-50577
(Commission File
Number) 33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100, Berkeley,
(Address of Principal Executive Offices) CA 94710
(Zip Code)

Registrant’s telephone number, including area code: (510) 848-5100

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01     Entry into a Material Definitive Agreement.

     On November 2, 2005, Dynavax Technologies Corporation (“Dynavax” or the “Company”) appointed Ms. Nancy Buc as a director of the Company. Ms. Buc’s compensation package, as described below in Item 5.02, is hereby incorporated by reference.

Item 5.02.     Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

     On November 2, 2005, the Company appointed Ms. Nancy Buc as a director of the Company. Ms. Buc will serve as one of the Company’s Class II directors until the 2008 annual meeting of stockholders or until her earlier resignation or removal.

     In connection with her joining the Board, Ms. Buc was granted on November 2, 2005 an option to purchase 20,000 shares of common stock (vesting in four equal installments on each anniversary of the grant date), and will receive subsequent annual grants at the stockholders’ meetings (with 5,000 shares at the 2006 meeting, and 10,000 shares at each annual stockholders’ meeting thereafter) which vest in full on the one-year anniversary of the grant date. Ms. Buc will also receive an annual retainer of $20,000, and an additional $2,000 for each board meeting attended in person and $500 for each board meeting attended by telephone.

     The press release issued by the Company announcing Ms. Buc’s appointment to the board of directors is attached as Exhibit 99.1.

Item 9.01     Financial Statements and Exhibits.

     (c) Exhibits.

     99.1     Press release of Dynavax Technologies Corporation, dated November 2, 2005.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Dynavax Technologies Corporation
Date: November 8, 2005	By:	/s/ Timothy G. Henn
		Timothy G. Henn
		Vice President, Finance and Administration

EX-99.1

Exhibit 99.1

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Contact:
Dynavax Technologies Corporation
Jane M. Green, PhD
Vice President, Corporate Communications
Phone (510) 665-4630
Email: jgreen@dvax.com

DYNAVAX APPOINTS NANCY L. BUC, FORMER FDA CHIEF COUNSEL,
TO ITS BOARD OF DIRECTORS

Berkeley, CA —November 2, 2005 — Dynavax Technologies Corporation (NASDAQ:DVAX) announced that Nancy L. Buc has joined the Company’s Board of Directors. Ms. Buc is a partner in the Washington, DC law firm Buc & Beardsley, and has had a long a distinguished legal career with a strong focus on healthcare policy and government service. Ms. Buc formerly served as Chief Counsel for the U.S. Food and Drug Administration. During an earlier period of government service, she served successively as Attorney-Advisor to the Chairman of the Federal Trade Commission (FTC) and Assistant Director of the FTC’s Bureau of Consumer Protection.

“Nancy’s knowledge of the pharmaceutical regulatory environment and her broad experience in strengthening the interface between government and industry will be valuable assets to Dynavax as our clinical programs progress and our company matures,” said Dino Dina, MD, president and chief executive officer. “Nancy’s advocacy on behalf of biotechnology companies provides her with a unique perspective on the development and regulatory challenges biotechnology companies face in preparing for their commercial stage of development. We believe that her skills will be highly complementary to the expertise we possess internally and to that of our Board.”

Ms. Buc has served as a member of several major government panels, including the National Institutes of Health (NIH) Recombinant DNA Advisory Committee, the NIH Consensus Panel on Effective Medical Treatment of Heroin Addiction, and the Office of Technology Assessment’s Advisory Panels on Government Policies and Pharmaceutical Research and Development and New

Developments in Biotechnology. She was also a member of the Institute of Medicine’s committees on Contraceptive Research and Development and NIDA Medications Development. She is also a member of the Food and Drug Law Institute’s Board of Directors.

Ms. Buc received her Bachelor of Arts degree from Brown University, her Bachelor of Law degree from the University of Virginia, and was awarded an honorary doctor of laws degree from Brown University. She has served as both a trustee and a fellow on the Brown University Corporation, Brown’s governing body. She is a director of the National Partnership for Women and Families.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax’s pipeline includes: a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial, and in a supportive clinical trial in ragweed allergic children; a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.

Dynavax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements regarding statements related to plans to advance its clinical programs in ragweed allergy, hepatitis B and cancer and the commercial opportunities for those programs. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” ”slated,” “goal” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Dynavax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Dynavax’s business including, without limitation, risks relating to: the progress and timing of its anticipated Phase 3 clinical trials in ragweed allergy and hepatitis B; difficulties or delays in developing, testing, obtaining regulatory approval of, producing and marketing its products; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to maintain effective financial planning and internal controls; and other risks detailed in the “Risk Factors” section of Dynavax’s Annual Report on Form 10-K filed on March 18, 2005, Dynavax’s quarterly report on Form 10-Q filed on May 9, 2005 and Dynavax’s Prospectus Supplement filed on October 11th, 2005. You are

cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.